A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy

The requested reference [9c5a66a7d4cfb5c78ab711fba8f4380a0c6779f4] no longer exists in our database. It has been replaced by the current reference: [48c6226adbc0071a3981449d659ad22c5143cb9f]

Authors Mato, A.R., Schuster, S.J., Lamanna, N., Flinn, I., Barrientos, J.C., Kambhampati, S. -More
Category Primary study
JournalJournal of Clinical Oncology
Year 2018
Links DOI
This article has no abstract
Epistemonikos ID: 7165c63e33714132c854cb05e75ba554cbbb6165
First added on: Feb 10, 2025